To emphasize the need for validated clinician-informed benchmarks for effective use of AI in interpreting continuous glucose monitoring (CGM) data.
Key Findings:
CGM interpretation varies significantly among clinicians.
Variability is influenced by patient-specific factors, behavioral influences, and contextual features.
The Glycemia Risk Index (GRI) correlates more closely with clinician judgment than individual metrics.
Interpretation:
For AI tools to be clinically meaningful and safe, they must be developed using benchmarks that reflect expert clinical interpretation of CGM data.
Limitations:
Current benchmarks may not adequately represent all patient subpopulations.
The reliance on clinician judgment may introduce subjective variability.
Conclusion:
Developing standardized benchmarks is crucial for the effective integration of AI in diabetes care, ensuring that AI tools align with clinical practices and improve patient outcomes.
AACE Endocrine AI
is published by Conexiant under a license arrangement with the American Association of Clinical Endocrinology, Inc. (AACE®). The ideas and opinions expressed in
AACE Endocrine AI do not necessarily reflect those of Conexiant or AACE. For more information, see Policies.